UCSF

Running trials

• Recruiting

  Understanding the Neural Underpinnings of Risk-Taking Behavior in Psychiatric Disease

  NCT07896343· Source

• Not yet recruiting

  A Prospective, Randomized Multicenter Clinical Trial of the TricValve® Transcatheter Bicaval Valve System in Subjects With Severe Tricuspid Regurgitation.

  NCT06458907· Source

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Source

• Recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

  NCT07326709· Phase 3· Source

• Recruiting

  A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT07287150· Phase 2· Source

• Recruiting

  A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

  NCT07491497· Phase 1/2· Source

• Recruiting

  A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

  NCT07061574· Phase 1/2· Source

• Enrolling by invitation

  Movement State-dependent Adaptive DBS for PD

  NCT07424508· Source

• Recruiting

  A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

  NCT07321106· Phase 1· Source

• Recruiting

  A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07116616· Phase 1/2· Source

• Enrolling by invitation

  Interleukin-15 to Promote Post-ART Control of HIV

  NCT07145164· Phase 2· Source

• Recruiting

  A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

  NCT06624644· Phase 2/3· Source

• Recruiting

  A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

  NCT07066657· Phase 1· Source

• Recruiting

  A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

  NCT07075185· Phase 1· Source

• Recruiting

  DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

  NCT06805305· Phase 2· Source

• Recruiting

  A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

  NCT06585774· Phase 3· Source

• Active, not recruiting

  Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis

  NCT06444113· Phase 4· Source

• Active, not recruiting

  Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

  NCT06655896· Phase 2· Source

• Active, not recruiting

  A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

  NCT06581198· Phase 2· Source

• Active, not recruiting

  TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)

  NCT06137807· Source

• Active, not recruiting

  A Phase 1b Study of WU-NK-101 in Combination With Cetuximab

  NCT05674526· Phase 1· Source

• Recruiting

  An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

  NCT05939414· Phase 3· Source

• Recruiting

  Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr

  NCT05948657· Source

• Active, not recruiting

  An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

  NCT06129240· Source

• Active, not recruiting

  ULTRA-HFIB-Redo: Ultrasound-based Renal Sympathetic Denervation vs Control in Redo Ablation Patients

  NCT05988411· Source

• Recruiting

  Human/Machine Interface: What the HeartMate 3 ® Device Tells Us About the Future

  NCT06039176· Source

• Active, not recruiting

  Shoulder iD™ Primary Reversed Glenoid Outcomes Clinical Study

  NCT05868148· Source

• Active, not recruiting

  Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

  NCT05838768· Phase 1· Source

• Recruiting

  Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

  NCT05395624· Phase 1/2· Source

• Active, not recruiting

  A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors

  NCT05653882· Phase 1· Source

• Active, not recruiting

  Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

  NCT05462717· Phase 1· Source

• Recruiting

  Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II

  NCT05102019· Source

• Active, not recruiting

  A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

  NCT04923893· Phase 3· Source

• Active, not recruiting

  Adaptive Deep Brain Stimulation to Improve Motor and Gait Functions in Parkinson's Disease

  NCT04675398· Source

• Recruiting

  Medial-prefrontal Enhancement During Schizophrenia Systems Imaging

  NCT04807530· Source

• Active, not recruiting

  Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers

  NCT04404595· Phase 1/2· Source

• Recruiting

  Predicting BCG Response

  NCT04564781· Source

• Active, not recruiting

  A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

  NCT04175600· Phase 3· Source

• Active, not recruiting

  Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)

  NCT03915184· Phase 1/2· Source

• Recruiting

  The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

  NCT03509961· Phase 2· Source

• Active, not recruiting

  Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

  NCT02947685· Phase 3· Source

• Active, not recruiting

  Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)

  NCT02661451· Source

• Active, not recruiting

  Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

  NCT02091245· Phase 1· Source

• Active, not recruiting

  Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

  NCT01892722· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer3 recruiting
• Colorectal cancer2 recruiting
• Heart failure2 recruiting
• Multiple myeloma2 recruiting
• Parkinson disease2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• ALS (motor neurone disease)1 recruiting
• Alzheimer disease1 recruiting
• Bladder cancer1 recruiting
• Childhood cancers1 recruiting
• Coronary artery disease1 recruiting
• Depression1 recruiting
• Gastric and esophageal cancer1 recruiting
• Glioblastoma1 recruiting
• High blood pressure1 recruiting
• HIV1 recruiting
• Huntington's disease1 recruiting
• Lung cancer1 recruiting
• Melanoma1 recruiting
• Multiple sclerosis1 recruiting
• Pancreatic cancer1 recruiting
• Schizophrenia1 recruiting
• Stroke1 recruiting
• Type 1 diabetes1 recruiting
• Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  NE3107 in Adults With Neurological Symptoms of Long COVID

  NCT06847191· Phase 2· Source

• Completed

  Designing Team Clinic for Youth With Type 2 Diabetes

  NCT06658743· Source

• Recruiting

  A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

  NCT06586957· Phase 1· Source

• Completed

  A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer

  NCT06188559· Phase 2· Source

• Terminated

  Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

  NCT05712694· Phase 3· Source

• Completed

  IS-002 Phase 2 Prostate Cancer Study

  NCT05946603· Phase 2· Source

• Completed

  Genetic Testing in Autosomal Dominant Polycystic Kidney Disease

  NCT06085807· Source

• Terminated

  A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM

  NCT05370508· Phase 1/2· Source

• Completed

  Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial

  NCT05590585· Phase 4· Source

• Completed

  DORAYA-HF Early Feasibility Study

  NCT05206422· Source

• Terminated

  Napping, Sleep, Cognitive Decline and Risk of Alzheimer's Disease

  NCT03256539· Source

• Terminated

  A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma

  NCT04740034· Phase 1· Source

• Completed

  Deciphering Principles of Network Dynamics Underlying Depression Symptom Severity From Multi-day Intracranial Recordings in Patients With Major Depression

  NCT06953362· Source

• Terminated

  A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

  NCT04459715· Phase 3· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Source

• Completed

  A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)

  NCT03987295· Phase 2· Source

• Recruiting

  Extension Study for the Port Delivery System With Ranibizumab (Portal)

  NCT03683251· Phase 3· Source

• Completed

  Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

  NCT03056755· Phase 2· Source

• Terminated

  Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies

  NCT02900651· Phase 1· Source